We reviewed the underlying accounting records for the six entities that we audited and determined that, during our audit period, all six entities adhered to the 5 percent limit on the use of Proposition 56 funding for administrative costs
JAMA 274:234240 Glantz SA, Barnes DE, Bero L, Hanauer P, Slade J (1995) Looking through a keyhole at the tobacco industry
At least I had not carried EVERYTHING down with us
10.1152/physrev.00034.2006 66 HolsteinA.BeilW
The FDA and the National Institutes of Health recently published a paper outlining that while getting smokers to quit is the gold standard, it might consider therapies that prove clinically meaningful reductions in smoking. The Center for Drug Evaluation and Research is not just encouraging drug development in this space, an FDA official said during a public meeting in October to discuss the regulators evolving approach to approving smoking cessation therapies, we are in fact rolling out the red carpet and very strongly supporting it. The goal of this product is not to replicate the nicotine delivery of a cigarette, says Qnovia CEO Brian Quigley, because we're not trying to get people to use this forever. The design of the RespiRx was inspired by e-cigarettes and vapes but uses medical grade dosing to deliver a precise amount of nicotine every day over a 12-week program
